Efficacy of human β-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters

Peptides

Volumn 25, Issue 11, 2004, Pages 1873-1881

  Sharma, Preeti ^a   Singh, Nasib ^a   Garg, Ravendra ^a   Haq, Wahajul ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Combination therapy; Human casein; Macrophage migration index; Non specific resistance; Sodium antimony gluconate

Indexed keywords

ANTIMONY GLUCONATE; BETA CASEIN; BETA CASEIN FRAGMENT [54-59]; COMPOUND 89 215; MURAMYL DIPEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL INFECTION; FOOD; HAMSTER; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; INFECTION RESISTANCE; LEISHMANIA DONOVANI; LEISHMANIASIS; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROPHYLAXIS; VISCERAL LEISHMANIASIS;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; AMINO ACID SEQUENCE; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CASEINS; CELLS, CULTURED; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HOST-PARASITE RELATIONS; HUMANS; INJECTIONS, INTRAPERITONEAL; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES, PERITONEAL; MALE; MESOCRICETUS; PEPTIDE FRAGMENTS; TIME FACTORS;

CRICETINAE; LEISHMANIA DONOVANI;

EID: 6344267058     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2004.06.011     Document Type: Article

References (38)

1. A. Adam, R. Ciorbaru, F. Ellouz, J.F. Petit, and E. Lederer Adjuvant activity of monomeric bacterial cell wall peptidoglycans Biochem. Biophys. Res. Commun. 59 1974 561 567
2. L.E. Adinolfi, P.F. Bonventre, M.V. Pas, and D.A. Eppstein Synergistic effects of glucantime and liposome encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis Infect. Immun. 48 1985 409 416
3. R. Badaro, E. Falcoff, F.S. Badaro, E.M. Carvalho, D. Pedral-Sampaio, and J.S. Carvalho Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma N. Engl. J. Med. 322 1990 16 21
4. B.J. Berger, and A.H. Fairlamb Interaction between immunity and chemotherapy in the treatment of trypanosomiasis and leishmaniasis Parasitology 105 1992 S71 S78
5. E.M. Carvalho, O. Bacellar, C. Brownell, T. Regis, R.L. Coffman, and S.G. Reed Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis J. Immunol. 152 1994 5949 5956
6. E.M. Carvalho, R.S. Teixeira, and W.D. Johnson Jr. Cell mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection Infect. Immun. 33 1981 498 500
7. J.A. Cook, T.W. Holbrook, and B.W. Parker Visceral leishmaniasis in mice: protective effect of glucan J. Reticuloendothel. Soc. 27 1980 567 573
8. M.J. Doenhoff, J. Modha, J.R. Lambertucci, and D.J. McLaren The immune dependence of chemotherapy Parasitol. Today 7 1991 16 18
9. F.A. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives Biochem. Biophys. Res. Commun. 59 1974 1317 1325
10. E. Falcoff, N.J. Taranto, and C.E. Remondegui Clinical healing of antimony resistant cutaneous or mucpcutaneous leishmaniasis following the combined administration of IFN-γ and pentavalent antimonial compounds Trans. R. Soc. Trop. Med. Hyg. 88 1 1994 95 97
11. C.G. Haidaris, and P.F. Bonventre Efficacy of combined immunostimulation and chemotherapy in experimental visceral leishmaniasis Am. J. Trop. Med. Hyg. 32 1983 286 295
12. M. Ho, D.K. Koech, D.W. Iha, and AD.M. Bryceson Immunosuppression in Kenyan visceral leishmaniasis Clin. Exp. Immunol. 51 1983 207 214
13. M.U. Iwobi, M.J. Doenhoff, and R.A. Neal Immune-dependence of chemotherapy of experimental visceral leishmaniasis Trans. R. Soc. Trop. Med. Hyg. 85 1991 56 57
14. S. Lein, and H.B. Lowman Therapeutic peptides Trends Biotechnol. 21 12 2003 556 562
15. I. Lowy, C. Bona, and D. Chedid Target cells for the activity of a synthetic adjuvant: muramyl dipeptide Cell Immunol. 29 1977 195 199
16. K.N. Masihi Immunomodulators in infectious diseases: panoply of possibilities Int. J. Immunopharmacol. 22 2000 1083 1091
17. P.C. Melby, B. Chandrasekar, W. Zhao, and J.E. Coe The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response J. Immunol. 166 2001 1912 1920
18. D. Migliore-Samour, J. Bouchadon, F. Floc'h, A. Zerial, L. Ninet, G.H. Werner, and P. Jolles A short lipopeptide, representative of a new family of immunological adjuvants devoid of sugar Life Sci. 26 1980 883 888
19. H.W. Murray, J.D. Berman, and S.D. Wright Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony J. Infect. Dis. 157 1988 973 978
20. H.W. Murray, Hariprasad, and E.F. Richard Treatment of experimental visceral leishmaniasis in a 'T' cell-deficient host: response to amphotericin B and pentamidine Antimicrob. Agents Chemother. 37 1993 1504 1505
21. H.W. Murray, M.J. Oca, A.M. Granger, and R.D. Schreiber Requirement of 'T' cells and effect of lymphokines in successful chemotherapy for an intracellular infection J. Clin. Investig. 83 1989 1253 1257
22. R.A. Neal, and S.L. Croft An in vitro system for determining the activity of compounds against the intracellular amastigotes forms of Leishmania donovani J. Antimicrob. Chemother. 14 1984 463 475
23. R. Pal, Anuradha, P.Y. Guru, and J.C. Katiyar Leishmania donovani in hamster: migration of amastigotes to unusual sites following drug therapy Med. Sci. Res. 17 1989 579 581
24. R. Pal, Anuradha, S.Y. Rizvi, B. Kundu, K.B. Mathur, and J.C. Katiyar Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptide and impact on therapeutic efficacy Experientia 47 1991 486 490
25. 14C labeled) in mouse Int. Immunopharmacol. 1 1979 35 41
26. F. Parker, D. Miglipore-Samour, F. Floc'h, A. Zerial, G.H. Werner, J. Jolles, M. Casaretto, H. Zahn, and P. Jolles Immunostimulating hexapeptide from human casein: amino acid sequence, synthesis and biological properties Eur. J. Biochem. 145 1984 677 682
27. H.R. Rezai, A.B. Behbehani, S. Gettner, and S. Ardehali Effect of levimasloe on the course of experimental leishmaniasis in guinea pigs and mice: haematological and immunological findings Ann. Trop. Med. Parasitol. 82 1988 243 249
28. D.L. Sacks, S.L. Lal, S.N. Shrivastava, J. Blackwell, and F.A. Neva An analysis of 'T' cell responsiveness in Indian Kala-azar J. Immunol. 138 1987 908 913
29. R. Sahai, A. Puri, R.P. Saxena, R. Saran, W. Haq, B. Kundu, and K.B. Mathur Synthesis and immunostimulant activity of novel analogs of human casein fragment (54-59) Immunopharmacol. Immunotoxicol. 18 1996 511 528
30. K.C. Saxena, A. Puri, Sumati, R. Saxena, and R.P. Saxena Macrophage migration as an index of immune status Immunol. Invest. 20 1991 431 440
31. R. Sharan, B. Kundu, and K.B. Mathur Synthesis of immunostimulating hexapeptide corresponding to sequence (54-59) of human β-casein Indian J. Chem. 30B 1991 728 731
32. P. Sharma, Anuradha, A. Rohtagi, W. Haq, K.B. Mathur, and J.C. Katiyar Stimulation of nonspecific resistance by thymopentin and its analogs against Leishmania donovani infection in hamsters Peptides 20 1999 1381 1383
33. P. Sharma, Anuradha, R. Sharan, W. Haq, B. Kundu, J.C. Katiyar, and K.B. Mathur Stimulation of non-specific resistance by human β-casein fragment (54-59) and its synthetic analogues against Leishmania donovani infection Protein Peptide Lett. 3 1996 261 266
34. L.L. Smrkovski, and C.L. Larson Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice Infect. Immun. 16 1977 249 257
35. J.K. Srivastatava, A. Misra, P. Sharma, B. Srivastava, S. Naik, and A. Dube Prophylactic potential of autoclaved Leishmania donovani with BCG against experimrental visceral leishmaniasis Parasitology 127 2003 107 114
36. K. Sugimura, M. Vemiya, I. Saiki, I. Azuma, and Y. Yamamura The adjuvant activity of synthetic N-acetyl muramyl dipeptide: evidence of initial target cells for adjuvant activity Cell Immunol. 43 1979 137 149
37. S. Sundar Drug resistance in Indian visceral leishmaniasis Trop. Med. Int. Health 6 2001 849 854
38. K. Zehra, R. Pal, Anuradha, S.Y. Rizvi, W. Haq, B. Kundu, J.C. Katiyar, and K.B. Mathur Leishmania donovani in hamsters: stimulation of non-specific resistance by novel lipopeptides and their effect in antileishmanial therapy Experientia 51 1995 725 730